A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. - No Study Results Posted

A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. (HuLuc63-1702)

This study is currently recruiting participants.

Study NCT00726869 Information provided by Facet Biotech

First Received: July 29, 2008 Last Updated: October 14, 2009 History of Changes

No Study Results Posted for this Study

About Study Results Reporting

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	September 2010
Estimated Primary Completion Date:	September 2010 (Final data collection date for primary outcome measure)